MOH Strictly Opposes Price Collusion, Anti-competitive Practices In Medicine Procurement
PUTRAJAYA, The Ministry of Health (MOH) will not tolerate any form of exclusivity, price collusion, anti-competitive practices, or procurement management issues, which contribute to the increase in the cost of procurement of medicines. The MOH is particularly concerned about instances where pharmaceutical manufacturers and suppliers charge the government higher prices for certain products, compared with those offered in the private sector. ‘Especially single product registration holders, whether for patented or generic products registered with the National Pharmaceutical Regulatory Agency (NPRA),’ the ministry said in a statement today. In response, the MOH has conducted several engagement sessions with representatives from manufacturing